| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2478334 | Annales Pharmaceutiques Françaises | 2008 | 9 Pages |
Abstract
Radioimmunotherapy (RIT) is an emerging treatment option for non-Hodgkin's lymphoma. Only Zevalin® (Bayer Schering Pharma) radiolabeled with yttrium 90 (90Y) is approved in France for the treatment of adult patients with rituximab relapsed or refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. This radioimmunotherapeutic agent consists of ibritumomab, a murine anti-CD20 monoclonal antibody, conjugated to the metal chelator tiuxetan for retention of the beta emitter 90Y. This review presents the concept of RIT. The pharmacological characteristics of [90Y]-ibritumomab tiuxetan, the specificity of its preparation and its special precautions for use will be described. The other radionuclides and antibodies in development will also be mentioned.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
N. Rizzo-Padoin,